|Articles|September 1, 2004
- Pharmaceutical Executive-09-01-2004
September Table of Contents
September Table of Contents
Advertisement
Articles in this issue
about 21 years ago
September Table of Contentsover 21 years ago
(Huge) Untapped Opportunityover 21 years ago
Information Into Actionover 21 years ago
Halting the Hypeover 21 years ago
Spend Trends: A $20 Billion Bill and Plenty of Changeover 21 years ago
From the Mouths of Babesover 21 years ago
Safe and Secureover 21 years ago
Synta's Surpriseover 21 years ago
The New Building Blocks for Blockbustersover 21 years ago
Specialty Therapies Lose Special StatusNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Trending on PharmExec
1
Report: Richard Pazdur Out as Director of CDER
2
Pharmaceutical Commercialization: A 2026 Outlook Personalization and Precision Will Define a New Year in Pharma
3
Lilly Reduces Price of Zepbound Single-Dose Vials for Self-Pay Patients
4
Regeneron Announces $150 Million Collaboration with Tessera Therapeutics to Develop Gene Editing Therapy
5
